An n-of-1 Trial Service in Clinical Practice: Testing the Effectiveness of Liuwei Dihuang Decoction for Kidney-Yin Deficiency Syndrome

被引:13
作者
Huang Yuhong [1 ]
Liu Qian [2 ]
Liu Yu [1 ]
Zhao Yingqiang [1 ]
Li Yanfen [1 ]
Yu Shujing [2 ]
Qin Shufang [1 ]
Sun Lanjun [1 ]
Zou Shuxuan [1 ]
Wang Baohe [1 ]
机构
[1] Tianjin Univ Tradit Chinese Med, Affiliated Hosp 2, Tianjin, Peoples R China
[2] Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China
基金
中国国家自然科学基金;
关键词
D O I
10.1155/2013/827915
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective. To describe the clinical use of n-of-1 RCTs for kidney-Yin deficiency syndrome that is a traditional Chinese medicine syndrome in publicly clinical practice in China. Methods. Our study included patients with kidney-Yin deficiency syndrome, using a within-patient, randomized, double-blind, crossover comparison of Liuwei Dihuang decoction versus placebo. Outcome Measures. Primary outcome measures included number of individual completion rates, response rate, and post-n-of-1 RCTs decisions. Secondary measures were the whole group score of individual Likert scale, SF-36 questionnaire. Results. Fifty patients were recruited and 3 were not completed. Forty-seven patients completed 3 pairs of periods, 3 (6.38%) were responders, 28 (59.57%) were nonresponders, and 16 (34.05%) were possible responders. Doctors and patients used the trial results to making decision. Three responders stayed on the medication management, 28 nonresponders ceased the LDD, 7 patients of the 16 possible responders could not give clear decision, and the others kept the same medication station. Among the whole group, neither the individual Likert score nor the SF-36 showed any statistical differences between LDD and placebo. Discussion. More attention should be paid to choose experienced TCM doctor as investigator and keep the simulant same with test medication in n-of-1 RCTs of TCM and sufficiently biological half-life period of Chinese medicine compound.
引用
收藏
页数:7
相关论文
共 11 条
[1]   Spirulina did not ameliorate idiopathic chronic fatigue in four N-of-1 randomized controlled trials [J].
Baicus, Cristian ;
Baicus, Anda .
PHYTOTHERAPY RESEARCH, 2007, 21 (06) :570-573
[2]   EFFECT OF SHEN-QI-DI-HUANG DECOCTION ON REDUCING PROTEINURIA BY PRESERVING NEPHRIN IN ADRIAMYCIN-INDUCED NEPHROPATHY RATS [J].
Chen, Hongyu ;
Zhu, Qin ;
Tang, Xuanli ;
Min, Man ;
Jie, Leqin ;
Chen, Lijing .
AFRICAN JOURNAL OF TRADITIONAL COMPLEMENTARY AND ALTERNATIVE MEDICINES, 2011, 8 (04) :467-476
[3]   CONTROLLED TRIALS IN SINGLE SUBJECTS .1 VALUE IN CLINICAL MEDICINE [J].
JOHANNESSEN, T .
BMJ-BRITISH MEDICAL JOURNAL, 1991, 303 (6795) :173-174
[4]   Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae [J].
Li, Shao ;
Zhang, Bo ;
Jiang, Duo ;
Wei, Yingying ;
Zhang, Ningbo .
BMC BIOINFORMATICS, 2010, 11
[5]   The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? [J].
Lillie, Elizabeth O. ;
Patay, Bradley ;
Diamant, Joel ;
Issell, Brian ;
Topol, Eric J. ;
Schork, Nicholas J. .
PERSONALIZED MEDICINE, 2011, 8 (02) :161-173
[6]   An n-of-1 trial service in clinical practice:: Testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder [J].
Nikles, C. Jane ;
Mitchell, Geoffrey K. ;
Del Mar, Chris B. ;
Clavarino, Alexandra ;
McNairn, Norma .
PEDIATRICS, 2006, 117 (06) :2040-2046
[7]  
Ning L., 2000, J CHENGDU U TCM, V23, P46
[8]   Liuwei Dihuang Lowers Body Weight and Improves Insulin and Leptin Sensitivity in Obese Rats [J].
Perry, Benjamin ;
Zhang, Junzeng ;
Sun, Changhao ;
Saleh, Tarek ;
Wang, Yanwen .
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2012, 2012
[9]   Liuwei Dihuang (LWDH), a Traditional Chinese Medicinal Formula, Protects against β-Amyloid Toxicity in Transgenic Caenorhabditis elegans [J].
Sangha, Jatinder S. ;
Sun, Xiaoli ;
Wally, Owen S. D. ;
Zhang, Kaibin ;
Ji, Xiuhong ;
Wang, Zhimin ;
Wang, Yanwen ;
Zidichouski, Jeffrey ;
Prithiviraj, Balakrishnan ;
Zhang, Junzeng .
PLOS ONE, 2012, 7 (08)
[10]  
Shin I. S., 2012, COMPLEMENTARY ALTERN, V12